Trials / Recruiting
RecruitingNCT07014410
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
A Multicenter Phase II Clinical Study of Pyrotinib Combined With Dalpiciclib Combined With Letrozole in the Treatment of ER-positive and HER2-positive Advanced Breast Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.
Detailed description
This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. Patients receive pyrotinib 320mg/d, dalpiciclib 125mg/d, d1-21, q28d. One cycle is 28d.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pyrotinib dalpiciclib letrozole | ER positive HER2 positive advanced breast cancer patients are given pyrotinib+dalpiciclib+letrozole |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
- First posted
- 2025-06-11
- Last updated
- 2025-06-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07014410. Inclusion in this directory is not an endorsement.